A method for calculating the mean residence times of catenary metabolites.

Abstract:

:A method for calculating the mean residence times of metabolites in the body, systemic circulation, and peripheral tissue is described. The calculations require the AUC, AUMC, and derivatives of the plasma concentration versus time curves of the metabolite and its precursor. The method is applicable to metabolites with any precursor order and does not require separate administration of the metabolite. The approach is applied to published data for the primary and secondary metabolites of ketamine.

journal_name

Biopharm Drug Dispos

authors

Cheng HY

doi

10.1002/bdd.2510120503

subject

Has Abstract

pub_date

1991-07-01 00:00:00

pages

335-42

issue

5

eissn

0142-2782

issn

1099-081X

journal_volume

12

pub_type

杂志文章
  • Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable?

    abstract::The pharmacokinetic regularity of the murine monoclonal antibody ior EGF/r3 across mammals was studied using allometry. The allometric relationship between the volume of distribution and body weight (W) across mammalian species was characterized by the power equation V(d)=218.8 W(0.84) (r=0.92), and that for clearance...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.398

    authors: Ducongé J,Fernández-Sánchez E,Alvarez D

    更新日期:2004-05-01 00:00:00

  • Development of oral extended release formulations of 6-hydroxybuspirone.

    abstract::Reducing the maximum plasma concentration whilst maintaining the exposure was shown to ameliorate adverse events following the oral administration of 6-hydroxybuspirone. This observation, along with a desire to provide for once daily dosing of this compound, provided the basis for the development of an extended releas...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/bdd.1819

    authors: Nicholson SJ,Timmins P,Dockens RC,Connor A,Croop R,Ferrie P,Zeng J,Dennis AB,Wilding I

    更新日期:2012-12-01 00:00:00

  • Characterization of ethiofos absorption in the rat small intestine.

    abstract::The absorption characteristics of ethiofos were studied using the rat in situ intestine circulating perfusion technique. Slow absorption kinetics were observed for ethiofos with varying rates of absorption and metabolism/degradation in situ as a function of buffer and absorption enhancers. In most cases less than 10 p...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510120404

    authors: Geary RS,Swynnerton NF,Timmons SF,Mangold DJ

    更新日期:1991-05-01 00:00:00

  • Contribution of serum lipoproteins as carriers of antitumour agent RS-1541 (palmitoyl rhizoxin) in mice.

    abstract::The tumour uptake as well as the anti-tumour activity of RS-1541 (palmitoyl rhizoxin), a potent antineoplastic agent, were investigated in mice bearing M5076 sarcoma. After intravenous administration, 14C-RS-1541 preferentially bound to the lipoproteins, to which 14C-rhizoxin did not bind. 14C-RS-1541 showed persistin...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510150202

    authors: Tokui T,Kuroiwa C,Tokui Y,Sasagawa K,Kawai K,Kobayashi T,Ikeda T,Komai T

    更新日期:1994-03-01 00:00:00

  • Bioactivation of loxoprofen to a pharmacologically active metabolite and its disposition kinetics in human skin.

    abstract::Loxoprofen (LX) is a prodrug-type non-steroidal anti-inflammatory drug which is used not only as an oral drug but also as a transdermal formulation. As a pharmacologically active metabolite, the trans-alcohol form of LX (trans-OH form) is generated after oral administration to humans. The objectives of this study were...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.1945

    authors: Sawamura R,Sakurai H,Wada N,Nishiya Y,Honda T,Kazui M,Kurihara A,Shinagawa A,Izumi T

    更新日期:2015-09-01 00:00:00

  • Pharmacokinetics of dihydroartemisinin in Artekin tablets for single and repeated dosing in Chinese healthy volunteers.

    abstract::Aim. To study the pharmacokinetics of dihydroartemisinin (DHA) in Artekin (compound dihydroartemisinin) tablets in Chinese healthy volunteers. Methods. Eighteen healthy volunteers (9 males, 9 females) received Artekin tablets for oral administration. The plasma samples of DHA were analysed by liquid-liquid extraction ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章

    doi:10.1002/bdd.607

    authors: Hong X,Liu CH,Huang XT,Huang TL,Ye SM,Ou WP,Wang NS,Mi SQ

    更新日期:2008-05-01 00:00:00

  • In vivo predictive release methods for medicated chewing gums.

    abstract::Understanding the performance of a drug product in vivo plays a key role in the development of meaningful in vitro drug release methodology. In case of functional chewing gums, the mode and the mechanism of release and the site of application differ significantly from other conventional solid oral dosage forms and req...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.1796

    authors: Gajendran J,Kraemer J,Langguth P

    更新日期:2012-10-01 00:00:00

  • The effect of oral dose volume on the absorption of a highly and a poorly water-soluble drug in the rat.

    abstract::The influence of dose volume on drug absorption following oral administration of a highly and a poorly water soluble drug was examined in male Sprague-Dawley rats. A constant mass of each 14C-labeled compound was given via gavage in dose volumes of 1, 5, 10, and 20 mL kg-1. Blood levels, as well as the quantitative ex...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510150508

    authors: Nickerson DF,Weaver ML,Tse FL

    更新日期:1994-07-01 00:00:00

  • Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor.

    abstract:PURPOSE:The chromone derivative MBL-II-141, specifically designed to inhibit ABCG2, was previously demonstrated to combine strong inhibition potency, low toxicity and good efficiency in reversing resistance to irinotecan in a xenografted mouse model. Here, the pharmacokinetic interactions in mice between irinotecan, it...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2069

    authors: Hénin E,Honorat M,Guitton J,Di Pietro A,Payen L,Tod M

    更新日期:2017-07-01 00:00:00

  • Pharmacokinetics of D-propranolol following oral, intra-arterial and intraportal administration: contrasting effects of oral glucose pretreatment.

    abstract::Several research groups have reported that in man the oral administration of propranolol with food leads to a marked increase (about 50 per cent) in the area under the plasma concentration-time curve (AUCpo) of this well absorbed and highly metabolized drug. An acute change in hepatic metabolic enzyme activity has bee...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510140305

    authors: Chow HH,Lalka D

    更新日期:1993-04-01 00:00:00

  • Inhibition of rat hepatic mitochondrial aldehyde dehydrogenase isozymes by repeated cyanamide administration: pharmacokinetic-pharmacodynamic relationships.

    abstract::The inhibition of rat hepatic mitochondrial aldehyde dehydrogenase (ALDH) isozymes was studied in apparent steady-state conditions after repeated intra-peritoneal cyanamide administration. The low-Km mitochondrial ALDH isozyme was more susceptible to cyanamide-induced inhibition (DI50 = 0.104 mg kg-1) than the high-Km...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510140508

    authors: Pruñonosa Piera J,Obach R,Sagristá ML,Bozal J

    更新日期:1993-07-01 00:00:00

  • A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer.

    abstract::Potential differences in pharmacokinetics (PK) between healthy subjects and patients with cancer were investigated using a physiologically based pharmacokinetic approach integrating demographic and physiological data from patients with cancer. Demographic data such as age, sex and body weight, and clinical laboratory ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.1830

    authors: Cheeti S,Budha NR,Rajan S,Dresser MJ,Jin JY

    更新日期:2013-04-01 00:00:00

  • Formulation and biopharmaceutical evaluation of a transdermal patch containing letrozole.

    abstract::The purpose of this study was to formulate a drug-in-adhesive (DIA) transdermal patch containing letrozole, a third generation aromatase inhibitor for the treatment of breast cancer, using pressure-sensitive-adhesives (PSAs) and to evaluate the percutaneous penetration and pharmacokinetics of letrozole after transderm...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.698

    authors: Li L,Fang L,Xu X,Liu Y,Sun Y,He Z

    更新日期:2010-03-01 00:00:00

  • The effect of caffeine on the pharmacokinetics of acetaminophen in man.

    abstract::The influence of caffeine (60 mg) was studied on the pharmacokinetic characteristics of acetaminophen (500 mg single dose) in ten healthy male human volunteers in a complete cross-over design. A high-performance liquid chromatography (HPLC) method was used to analyse serum drug concentrations. Caffeine caused a highly...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章

    doi:10.1002/bdd.2510160606

    authors: Iqbal N,Ahmad B,Janbaz KH,Gilani AU,Niazi SK

    更新日期:1995-08-01 00:00:00

  • The relative bioavailability of a commercial propranolol hydrochloride tablet in man.

    abstract::A relative bioavailability study of conventional tablet of propranolol hydrochloride was conducted in a group of 18 healthy volunteers employing the innovator's product as the reference tablet formation. Based on plasma levels of propranolol for the 24 h following administration of 2 x 40 mg oral propranolol hydrochlo...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/bdd.2510030204

    authors: Roscoe R,Cooper J,Wilson TW,Joshi NN,Midha KK

    更新日期:1982-04-01 00:00:00

  • Effect of telaprevir on the metabolism and hepatic uptake of tacrolimus (FK506).

    abstract::Telaprevir, a chronic hepatitis C virus (HCV) protease inhibitor, is known to be a cytochrome P450 (CYP) 3A4/5 substrate and inhibitor. In the present study, the in vitro inhibitory effect of telaprevir on the metabolism of tacrolimus in human liver microsomes was investigated using 13-O-demethyltacrolimus (M-I) as a ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.1913

    authors: Oda K,Yamano K

    更新日期:2014-12-01 00:00:00

  • Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits.

    abstract::The pharmacokinetics and pharmacodynamics of torasemide were evaluated after intravenous administration of the same total dose of torasemide at a dose of 1mg/kg to rabbits with different infusion times, 1 min (treatment I), 30 min (treatment II) and 2 h (treatment III). The loss of water and electrolytes in urine indu...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.401

    authors: Kim YC,Lee MG,Ko SH,Kim SH

    更新日期:2004-07-01 00:00:00

  • Single dose pharmacokinetics of HEPP, a new anticonvulsant in normal healthy volunteers.

    abstract::The pharmacokinetics and the dose proportionality of a new anticonvulsant compound, HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) was studied in healthy male volunteers as part of the pharmacological evaluation for new drugs. Study was performed administering doses of 250, 375, 500 and 625 mg of HEPP to six male v...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章

    doi:10.1002/(sici)1099-081x(199812)19:9<583::aid-bdd13

    authors: González-Esquivel DF,Rubio-Donnadieu F,Carvajal-Sandoval G,Jung HC

    更新日期:1998-12-01 00:00:00

  • Gender differences in pharmacokinetics of lumefantrine and its metabolite desbutyl-lumefantrine in rats.

    abstract::Lumefantrine has been reported to be mainly bio-transformed by cytochrome P450 isozyme 3A4 to desbutyl-lumefantrine (DLF) in human liver microsomes. Since CYP3A is expressed in a sex specific manner in rats, it could be expected that the pharmacokinetics of lumefantrine would be changed in male rats compared with thos...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.1786

    authors: Wahajuddin,Singh SP,Jain GK

    更新日期:2012-05-01 00:00:00

  • Pharmacokinetic and clinical parameters of zopiclone and trimipramine when administered simultaneously to volunteers.

    abstract::Zopiclone is a new sedative showing a rapid onset of hypnotic effect and a relatively short duration of action. The goal of this study was to assess the kinetic parameters of zopiclone and its interaction with trimipramine when administered concomitantly. Ten normal subjects each received doses of zopiclone (7.5 mg), ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/bdd.2510050205

    authors: Caille G,du Souich P,Spenard J,Lacasse Y,Vezina M

    更新日期:1984-04-01 00:00:00

  • The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine.

    abstract::In a double-blind, placebo-controlled, single-dose ascending pharmacokinetics and tolerance study, we evaluated the bispyridinium oxime HI-6 dichloride monohydrate (62.5, 125, 250, and 500 mg), administered intramuscularly with atropine sulphate, 2 mg, in 24 healthy male volunteers. The plasma HI-6 peak concentration ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/bdd.2510160506

    authors: Clement JG,Bailey DG,Madill HD,Tran LT,Spence JD

    更新日期:1995-07-01 00:00:00

  • Biopharmaceutics classification and intestinal absorption of chikusetsusaponin IVa.

    abstract::The objective of this study was to investigate the absorption behavior of chikusetsusaponin IVa (CHS-IVa) in the rat intestine using single-pass intestinal perfusion (SPIP) and to classify CHS-IVa into the biopharmaceutics classification system (BCS). The equilibrium solubility of CHS-IVa was determined by the shaker ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2200

    authors: Zhang W,Liu H,Liu C

    更新日期:2019-09-01 00:00:00

  • 1α,25-dihydroxyvitamin D3 on intestinal transporter function: studies with the rat everted intestinal sac.

    abstract::Previous studies have shown that 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) treatment (2.56 nmol/kg i.p. daily×4) increased PepT1, Mrp2, Mrp4, Asbt, but not Mdr1/P-gp in the rat small intestine. In this study, the intestinal everted sac technique, together with various select probes: mannitol (paracellular transport), gl...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.742

    authors: Maeng HJ,Durk MR,Chow EC,Ghoneim R,Pang KS

    更新日期:2011-03-01 00:00:00

  • Disposition of a silicon-containing amide, an inhibitor of acyl-CoA: cholesterol acyltransferase, in dog and rat.

    abstract::The pharmacokinetics of 3-(decyldimethylsilyl)-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide (DMPP), an inhibitor of acyl-CoA:cholesterol acyltransferase, have been studied in the dog and the rat using 14C and 3H dual-labelled drug. In both species, gastrointestinal absorption of DMPP was slow and incomplete, amount...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510080504

    authors: Tse FL,Jaffe JM

    更新日期:1987-09-01 00:00:00

  • The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers.

    abstract::The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg were investigated ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/(sici)1099-081x(199910)20:7<327::aid-bdd19

    authors: Kanerva H,Kilkku O,Heinonen E,Helminen A,Rouru J,Tarpila S,Scheinin M,Huupponen R,Klebovich I,Drabant S,Urtti A

    更新日期:1999-10-01 00:00:00

  • Effect of dietary fibers on losartan uptake and transport in Caco-2 cells.

    abstract::The objective of this study was to assess the effect of dietary fibers on the transport of losartan, an angiotensin II type 1 receptor blocker, in small intestinal cells. Using Caco-2 cells in vitro, losartan uptake and transport were evaluated in the presence of various fibers (cellulose, chitosan, sodium alginate an...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2004

    authors: Iwazaki A,Takahashi N,Miyake R,Hiroshima Y,Abe M,Yasui A,Imai K

    更新日期:2016-05-01 00:00:00

  • Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype.

    abstract::Pharmacokinetic studies of riluzole show a large inter-individual variability of the drug's clearance and serum concentrations. Optimizing the individual dosage of riluzole may have the potential to improve the effect of riluzole treatment on survival of patients with amyotrophic lateral sclerosis (ALS). Limited data ...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 临床试验,杂志文章

    doi:10.1002/bdd.594

    authors: van Kan HJ,van den Berg LH,Groeneveld GJ,van der Straaten RJ,van Vught PW,Lie-A-Huen L,Guchelaar HJ

    更新日期:2008-04-01 00:00:00

  • The single-point method of dosage prediction: pharmacokinetic basis and method optimization.

    abstract::Based on the principle of superposition an expression has been established relating a drug concentration at steady-state to a concentration after a single dose. This relationship applies for drugs with linear pharmacokinetics given at equal dosage intervals and it is independent of the route of administration. The rel...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510030302

    authors: Love BL,Tsuei SE,Thomas J,Nation RL

    更新日期:1982-07-01 00:00:00

  • Use of a limited physiologic model to explain target organ toxicity of bupivacaine as a function of route of administration.

    abstract::A physiologic model to describe bupivacaine uptake by and elimination from brain and heart was developed. Preliminary validation of the model was accomplished by comparing concentration data predicted by the model with those determined in rabbits. The model was modified to examine similarities and differences followin...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510070204

    authors: Denson DD,Thompson GA,Coyle DE

    更新日期:1986-03-01 00:00:00

  • Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs.

    abstract::A new sustained release dosage form of valproic acid (VPA) was developed. The new sustained release dosage form was administered (twice, with and without food) to five dogs in comparison to a standard tablet (Depakine, Labaz) and an i.v. preparation of the drug. Drug level monitoring in the plasma was performed by a G...

    journal_title:Biopharmaceutics & drug disposition

    pub_type: 杂志文章

    doi:10.1002/bdd.2510050102

    authors: Bialer M,Friedman M,Dubrovsky J

    更新日期:1984-01-01 00:00:00